Dr. Anca Dinu Askanase | Source | Director of the Lupus Center, Rheumatologist, and Professor of Medicine at C...
Dr. Anca Dinu Askanase
Dr. Anca recently joined the CUMC Rheumatology faculty where she is the founder and clinical director of Columbia's new Lupus Center and the Director of Rheumatology Clinical Trials. She is an internationally renowned clinician, diagnostician and researcher with more than 15 years specializing in complex Systemic Lupus Erythematosus (SLE). Dr. Askanase trained as a rheumatologist at New York University where she remained for more than 15 years on faculty, directing clinical trials, training fellows and residents, and treating challenging cases of SLE at NYU's prestigious Hospitals.
-
Columbia University Irving Medical Center
Director of the Lupus Center, Rheumatologist, and Professor of Medicine
-
Small study, seismic implications: Exploring the promise, challenges of CAR T in lupus
It is not often that a single data set has the potential to fundamentally alter the treatment landscape for a disease in rheumatology, but recent findings on the use of chimeric antigen receptor T-cells in lupus may eventually do just that.The study at hand was published by Andreas Mackensen, MD, Georg Schett, MD — both of Friedrich Alexander University Erlangen-Nürnberg, in Germany —
Article
-
Columbia Expert on Massage Therapy for Ankylosing Spondylitis
Dr. Anca Askanase, a leading rheumatologist, is available to discuss massage therapy's potential benefits for ankylosing spondylitis. She offers insights into how this therapy might help manage the condition. -
Columbia Expert Weighs in on GLP-1 Use for Psoriatic Arthritis
Dr. Askanase is available to discuss the potential benefits and drawbacks of GLP-1 drugs for psoriatic arthritis patients. Her expertise could shed light on whether these drugs help with inflammation and improve patient outcomes through weight loss.
-
It is possible that CAR-T therapy will cure lupus. However, this therapy is not for everyone — the patients in the Schett paper had life-threatening lupus. Because of the heterogeneity of lupus, some patients may not benefit from it, and we will need to do the work to fully understand the safety and efficacy of CAR T in lupus patients. Several biotech companies have received clearance to proceed with the development of CAR-T products, and we and others are fully committed to do our part as investigators in these studies to bring these products to lupus patients,
